Evidence map›Paper›PMID 25926648›Full record

ArticleJournal of virology2015

Recombination of Globally Circulating Varicella-Zoster Virus.

Peter Norberg, Daniel P Depledge, Samit Kundu, Claire Atkinson, Julianne Brown, Tanzina Haque, Yusuf Hussaini, Eithne MacMahon, Pamela Molyneaux, Vassiliki Papaevangelou and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 92 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Varicella-Zoster Virus-Genetics, Molecular Evolution and Recombination.Current topics in microbiology and immunology · 2023
    Article
  12. Article
  13. Varicella Zoster Virus Neuronal Latency and Reactivation Modeled in Vitro.Current topics in microbiology and immunology · 2023
    Review
  14. Article
  15. Human herpesvirus diversity is altered in HLA class I binding peptides.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 5 countries.

Peter Norberg
Daniel P Depledge
Samit Kundu
Claire Atkinson
Julianne Brown
Tanzina Haque
Yusuf Hussaini
Eithne MacMahon
Pamela Molyneaux
Vassiliki Papaevangelou
Nitu Sengupta
Evelyn S C Koay
Julian W Tang
Gillian S Underhill
Anna Grahn
Marie Studahl
Judith Breuer
Tomas Bergström
University of Gothenburg · SEUniversity College London · GBAberdeen Royal Infirmary · GBAhmadu Bello University · NGGreat Ormond Street Hospital for Children NHS Foundation Trust · GBNational University Hospital · SGQueen Alexandra Hospital · GBSt Thomas' Hospital · GBUniversity General Hospital Attikon · GRUniversity Hospitals of Leicester NHS Trust · GB

Funding

Medical Research Council G0700814Medical Research Council G0900950MRF_ C0485
6 · The paper itself

Abstract

unlabelledVaricella-zoster virus (VZV) is a human herpesvirus, which during primary infection typically causes varicella (chicken pox) and establishes lifelong latency in sensory and autonomic ganglia. Later in life, the virus may reactivate to cause herpes zoster (HZ; also known as shingles). To prevent these diseases, a live-attenuated heterogeneous vaccine preparation, vOka, is used routinely in many countries worldwide. Recent studies of another alphaherpes virus, infectious laryngotracheitis virus, demonstrate that live-attenuated vaccine strains can recombine in vivo, creating virulent progeny. These findings raised concerns about using attenuated herpesvirus vaccines under conditions that favor recombination. To investigate whether VZV may undergo recombination, which is a prerequisite for VZV vaccination to create such conditions, we here analyzed 115 complete VZV genomes. Our results demonstrate that recombination occurs frequently for VZV. It thus seems that VZV is fully capable of recombination if given the opportunity, which may have important implications for continued VZV vaccination. Although no interclade vaccine wild-type recombinant strains were found, intraclade recombinants were frequently detected in clade 2, which harbors the vaccine strains, suggesting that the vaccine strains have already been involved in recombination events, either in vivo or in vitro during passages in cell culture. Finally, previous partial and complete genomic studies have described strains that do not cluster phylogenetically to any of the five established clades. The additional VZV strains sequenced here, in combination with those previously published, have enabled us to formally define a novel sixth VZV clade. IMPORTANCE: Although genetic recombination has been demonstrated to frequently occur for other human alphaherpesviruses, herpes simplex viruses 1 and 2, only a few ancient and isolated recent recombination events have hitherto been demonstrated for VZV. In the present study, we demonstrate that VZV also frequently undergoes genetic recombination, including strains belonging to the clade containing the vOKA strain.

Indexed as

Recombination, GeneticAdultChildChild, PreschoolCluster AnalysisDNA, ViralGenetic VariationGenome, ViralHerpesvirus 3, HumanHumansMolecular Sequence DataPhylogenySequence Analysis, DNASequence HomologyDNA, Viral

Identifiers

PMID25926648
PMCPMC4473579
OpenAlexW2077586716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.